
-
'Argentina with Cristina': Thousands rally for convicted ex-president
-
Guardiola hails new signings as Man City survive 'tough conditions'
-
Gaza rescuers say 33 killed by Israel fire
-
US approves Gilead's twice-yearly injection to prevent HIV
-
Khamenei vows Iran will never surrender, hypersonic missiles target Israel
-
Brazil says free of bird flu, will resume poultry exports
-
Lions boss Farrell says Test places still up for grabs
-
Climate change could cut crop yields up to a quarter
-
Hurricane Erick strengthens on approach to Mexico's Pacific coast
-
US Fed keeps interest rates unchanged in face of Trump criticism
-
South Africa captain Bavuma hails special Test triumph
-
Man City ease into Club World Cup campaign with win against Wydad
-
Pacers sweating on Haliburton injury ahead of NBA Finals clash
-
'Terrified': Supporters fear for prisoners trapped in Iran
-
South Africa moves closer to hosting Formula One race
-
Chelsea's Mudryk charged over anti-doping violation
-
Draper survives scare to reach Queen's quarter-finals
-
Pant hopes India can make country 'happy again' after plane crash
-
US Supreme Court upholds ban on gender-affirming care for minors
-
UK risks more extreme, prolonged heatwaves in future: study
-
Gosdens celebrate Royal Ascot double as Buick motors home on Ombudsman
-
Oil prices drop following Trump's Iran comments, US stocks rise
-
Musk's X sues to block New York social media transparency law
-
Iran-Israel war: a lifeline for Netanyahu?
-
Gaza Humanitarian Foundation initiative 'outrageous': UN probe chief
-
India's Pant glad of Anderson and Broad exits ahead of England Tests
-
Moth uses stars to navigate long distances, scientists discover
-
Hurricane Erick approaches Mexico's Pacific coast
-
Gaza flotilla skipper vows to return
-
Netherlands returns over 100 Benin Bronzes looted from Nigeria
-
Nippon, US Steel say they have completed partnership deal
-
Almeida takes fourth stage of Tour of Switzerland with injured Thomas out
-
World champion Olga Carmona signs for PSG women's team
-
Putin T-shirts, robots and the Taliban -- but few Westerners at Russia's Davos
-
Trump on Iran strikes: 'I may do it, I may not do it'
-
Khamenei vows Iran will never surrender
-
Bangladesh tighten grip on first Sri Lanka Test
-
England's Pope keeps place for India series opener
-
Itoje to lead Lions for first time against Argentina
-
Oil rises, stocks mixed as investors watch rates, conflict
-
Iran-Israel war: latest developments
-
Iran threatens response if US crosses 'red line': ambassador
-
Iranians buying supplies in Iraq tell of fear, shortages back home
-
UK's Catherine, Princess of Wales, pulls out of Royal Ascot race meeting
-
Rape trial of France's feminist icon Pelicot retold on Vienna stage
-
Khamenei says Iran will 'never surrender', warns off US
-
Oil prices dip, stocks mixed tracking Mideast unrest
-
How Paris's Seine river keeps the Louvre cool in summer
-
Welshman Thomas out of Tour of Switzerland as 'precautionary measure'
-
UN says two Iran nuclear sites destroyed in Israel strikes

US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
E.AbuRizq--SF-PST